Share Price and Basic Stock Data
Last Updated: January 3, 2026, 12:34 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Suven Life Sciences Ltd operates within the pharmaceuticals sector and has reported a current market capitalization of ₹3,749 Cr. The company’s revenue trajectory has shown significant volatility, with sales recorded at ₹14 Cr for FY 2023, a decline from ₹12 Cr in FY 2022. Quarterly sales figures reveal fluctuations, peaking at ₹4 Cr in both September 2022 and June 2023, but dropping to as low as ₹1 Cr in the most recent quarters. The trailing twelve months (TTM) sales stand at ₹6 Cr, indicating a downward trend in operational performance. The company has faced challenges in maintaining consistent revenue generation, as evidenced by the declining sales figures across multiple quarters, particularly from December 2023 to June 2025, where sales are expected to remain low. This revenue instability raises concerns about the company’s ability to sustain its operations effectively in a competitive market.
Profitability and Efficiency Metrics
Profitability metrics for Suven Life Sciences Ltd reflect severe challenges, with a reported net profit of -₹212 Cr, underscoring a critical financial strain. The operating profit margin (OPM) has plummeted to an alarming -8,671%, indicating substantial inefficiencies within the operational framework. Over the last few fiscal years, the company has consistently reported negative operating profits, with FY 2025 showing an operating profit of -₹166 Cr. The interest coverage ratio (ICR) stands at an extraordinary -3323.53x, suggesting that the company is not only unable to cover its interest obligations but is also under severe financial distress. The return on equity (ROE) and return on capital employed (ROCE) are recorded at 87.2% and 87.0%, respectively, but these figures are misleading as they stem from negative net profits. Hence, while the ratios may indicate high returns, they do not translate into actual profitability for the firm.
Balance Sheet Strength and Financial Ratios
The balance sheet of Suven Life Sciences Ltd reveals a lack of debt, as borrowings stand at ₹0 Cr, which is a positive aspect in terms of financial leverage. However, the company holds reserves of ₹259 Cr, down from ₹354 Cr in the previous fiscal year, indicating a depletion of financial buffers. The current ratio is reported at 3.21x, suggesting adequate liquidity to meet short-term obligations, yet this is juxtaposed against a declining asset base, which stood at ₹135 Cr in FY 2025. The price-to-book value (P/BV) ratio is exceptionally high at 22.48x, reflecting investor sentiment that may not be justified by the underlying financial health of the company. The enterprise value (EV) of ₹2,435.23 Cr, compared to its net operating revenue, reveals a stark contrast with EV/net operating revenue at 365.88x, highlighting potential overvaluation amidst deteriorating operational performance.
Shareholding Pattern and Investor Confidence
Investor confidence in Suven Life Sciences Ltd is reflected in its shareholding pattern, where promoters own 67.36% of the company, a slight decline from previous quarters. Foreign institutional investors (FIIs) hold 1.17%, while domestic institutional investors (DIIs) have increased their stake to 3.39%. The public holds 28.07%, and the total number of shareholders stands at 64,921. The gradual decline in promoter ownership may signal a lack of confidence in the company’s future prospects. The volatility in shareholding percentages, particularly among FIIs, suggests cautious sentiment in the market. Despite this, the relatively stable public holding indicates a base of retail investors who may still be optimistic about potential turnaround strategies. However, the overall low institutional interest may reflect concerns over the company’s financial metrics and operational challenges.
Outlook, Risks, and Final Insight
The outlook for Suven Life Sciences Ltd remains precarious given the significant financial challenges it faces. Key risks include the persistent negative profitability, high operational inefficiencies, and declining revenue trends that could further erode investor confidence. Additionally, the company’s inability to generate positive cash flows raises concerns about its sustainability in the long term. However, the absence of debt offers a buffer that could be advantageous if the company manages to implement effective restructuring strategies. If Suven can stabilize its revenue and improve operational efficiencies, it could potentially regain investor confidence and improve its financial standing. Conversely, continued losses without a clear turnaround strategy may lead to further declines in market valuation and shareholder confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 133 Cr. | 106 | 216/84.3 | 29.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,742 Cr. | 435 | 479/192 | 98.2 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.3 Cr. | 47.6 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 53.6 Cr. | 36.6 | 37.0/17.0 | 128 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,248.81 Cr | 1,149.28 | 54.07 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 3 | 3 | 4 | 3 | 2 | 2 | 1 | 3 | 2 | 1 | 2 | 1 |
| Expenses | 26 | 55 | 34 | 32 | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 |
| Operating Profit | -22 | -52 | -32 | -28 | -24 | -46 | -30 | -31 | -52 | -39 | -44 | -51 | -80 |
| OPM % | -494% | -1,719% | -1,208% | -737% | -768% | -1,885% | -1,267% | -3,024% | -2,032% | -2,435% | -2,981% | -2,714% | -8,671% |
| Other Income | 0 | 2 | 6 | 6 | 13 | 6 | 4 | 4 | 4 | 2 | 1 | 1 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 |
| Profit before tax | -23 | -51 | -28 | -24 | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 | -77 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | -4% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -23 | -51 | -28 | -24 | -13 | -42 | -27 | -28 | -50 | -39 | -44 | -52 | -77 |
| EPS in Rs | -1.06 | -2.34 | -1.27 | -1.10 | -0.58 | -1.91 | -1.22 | -1.29 | -2.28 | -1.79 | -2.01 | -2.36 | -3.40 |
Last Updated: December 28, 2025, 11:04 pm
Below is a detailed analysis of the quarterly data for Suven Life Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Jun 2025) to 1.00 Cr., marking a decrease of 1.00 Cr..
- For Expenses, as of Sep 2025, the value is 81.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 53.00 Cr. (Jun 2025) to 81.00 Cr., marking an increase of 28.00 Cr..
- For Operating Profit, as of Sep 2025, the value is -80.00 Cr.. The value appears to be declining and may need further review. It has decreased from -51.00 Cr. (Jun 2025) to -80.00 Cr., marking a decrease of 29.00 Cr..
- For OPM %, as of Sep 2025, the value is -8,671.00%. The value appears to be declining and may need further review. It has decreased from -2,714.00% (Jun 2025) to -8,671.00%, marking a decrease of 5,957.00%.
- For Other Income, as of Sep 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Jun 2025) to 4.00 Cr., marking an increase of 3.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -77.00 Cr.. The value appears to be declining and may need further review. It has decreased from -52.00 Cr. (Jun 2025) to -77.00 Cr., marking a decrease of 25.00 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -77.00 Cr.. The value appears to be declining and may need further review. It has decreased from -52.00 Cr. (Jun 2025) to -77.00 Cr., marking a decrease of 25.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is -3.40. The value appears to be declining and may need further review. It has decreased from -2.36 (Jun 2025) to -3.40, marking a decrease of 1.04.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:33 am
| Metric | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 117 | 521 | 499 | 543 | 625 | 286 | 13 | 13 | 12 | 14 | 12 | 7 | 6 |
| Expenses | 105 | 361 | 398 | 414 | 427 | 300 | 128 | 93 | 134 | 139 | 140 | 172 | 219 |
| Operating Profit | 13 | 159 | 102 | 129 | 198 | -14 | -116 | -80 | -122 | -126 | -128 | -166 | -214 |
| OPM % | 11% | 31% | 20% | 24% | 32% | -5% | -917% | -593% | -1,032% | -929% | -1,094% | -2,487% | -3,638% |
| Other Income | 3 | 9 | 19 | 21 | 23 | 27 | 14 | 8 | 5 | 14 | 29 | 11 | 7 |
| Interest | 5 | 5 | 6 | 6 | 5 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 12 | 18 | 21 | 21 | 11 | 4 | 4 | 4 | 7 | 6 | 6 | 6 |
| Profit before tax | 6 | 152 | 98 | 123 | 196 | 0 | -106 | -77 | -122 | -118 | -106 | -161 | -212 |
| Tax % | -32% | 28% | 26% | 29% | 37% | 15,038% | -11% | -7% | 0% | 0% | -1% | 0% | |
| Net Profit | 8 | 109 | 72 | 87 | 124 | -24 | -94 | -72 | -122 | -118 | -105 | -161 | -212 |
| EPS in Rs | 0.48 | 5.70 | 3.76 | 4.57 | 6.48 | -1.25 | -4.94 | -3.78 | -5.59 | -5.42 | -4.82 | -7.37 | -9.56 |
| Dividend Payout % | 35% | 7% | 35% | 15% | 15% | -80% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -33.94% | 20.83% | 42.53% | -119.35% | -291.67% | 23.40% | -69.44% | 3.28% | 11.02% | -53.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 54.78% | 21.70% | -161.88% | -172.31% | 315.07% | -92.85% | 72.72% | 7.74% | -64.35% |
Suven Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -35% |
| 5 Years: | -12% |
| 3 Years: | -17% |
| TTM: | -16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -24% |
| 3 Years: | -12% |
| TTM: | -58% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 36% |
| 3 Years: | 43% |
| 1 Year: | 40% |
| Return on Equity | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -62% |
| 3 Years: | -55% |
| Last Year: | -87% |
Last Updated: September 5, 2025, 1:41 pm
Balance Sheet
Last Updated: December 10, 2025, 3:29 am
| Month | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 | 22 | 22 | 22 | 23 |
| Reserves | 95 | 547 | 583 | 654 | 755 | 226 | 131 | 95 | 82 | 354 | 248 | 88 | 259 |
| Borrowings | 55 | 109 | 83 | 71 | 34 | 3 | 6 | 5 | 3 | 2 | 1 | 0 | 0 |
| Other Liabilities | 38 | 105 | 74 | 78 | 118 | 62 | 33 | 16 | 9 | 12 | 14 | 25 | 56 |
| Total Liabilities | 199 | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 337 |
| Fixed Assets | 110 | 172 | 305 | 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 | 60 | 58 |
| CWIP | 4 | 107 | 7 | 10 | 25 | 0 | 0 | 5 | 4 | 0 | 0 | 0 | 1 |
| Investments | 2 | 0 | 0 | 301 | 279 | 223 | 0 | 0 | 45 | 46 | 76 | 22 | 247 |
| Other Assets | 83 | 494 | 439 | 199 | 308 | 58 | 157 | 103 | 22 | 305 | 181 | 53 | 32 |
| Total Assets | 199 | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 337 |
Below is a detailed analysis of the balance sheet data for Suven Life Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 23.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 259.00 Cr.. The value appears strong and on an upward trend. It has increased from 88.00 Cr. (Mar 2025) to 259.00 Cr., marking an increase of 171.00 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 56.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 25.00 Cr. (Mar 2025) to 56.00 Cr., marking an increase of 31.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 337.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 135.00 Cr. (Mar 2025) to 337.00 Cr., marking an increase of 202.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 60.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 2.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 247.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 247.00 Cr., marking an increase of 225.00 Cr..
- For Other Assets, as of Sep 2025, the value is 32.00 Cr.. The value appears to be declining and may need further review. It has decreased from 53.00 Cr. (Mar 2025) to 32.00 Cr., marking a decrease of 21.00 Cr..
- For Total Assets, as of Sep 2025, the value is 337.00 Cr.. The value appears strong and on an upward trend. It has increased from 135.00 Cr. (Mar 2025) to 337.00 Cr., marking an increase of 202.00 Cr..
Notably, the Reserves (259.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -42.00 | 50.00 | 19.00 | 58.00 | 164.00 | -17.00 | -122.00 | -85.00 | -125.00 | -128.00 | -129.00 | -166.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 111 | 28 | 39 | 31 | 36 | 3 | 66 | 48 | 40 | 22 | 40 | 73 |
| Inventory Days | 200 | 165 | 183 | 222 | 329 | 0 | ||||||
| Days Payable | 157 | 89 | 78 | 91 | 134 | |||||||
| Cash Conversion Cycle | 154 | 105 | 144 | 162 | 231 | 3 | 66 | 48 | 40 | 22 | 40 | 73 |
| Working Capital Days | 139 | 49 | 55 | 42 | 82 | 23 | 704 | 1,084 | 234 | 265 | 101 | -440 |
| ROCE % | 8% | 13% | 15% | 24% | -4% | -54% | -58% | -118% | -53% | -36% | -87% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Flexi Cap Fund | 4,000,000 | 0.24 | 225.76 | N/A | N/A | N/A |
| Invesco India Contra Fund | 3,598,511 | 0.99 | 203.1 | 3,323,946 | 2025-12-14 11:28:18 | 8.26% |
| HDFC Balanced Advantage Fund | 3,353,052 | 0.18 | 189.25 | 2,500,285 | 2025-12-14 01:50:02 | 34.11% |
| DSP ELSS Tax Saver Fund | 3,285,254 | 1.06 | 185.42 | N/A | N/A | N/A |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 3,068,016 | 2.68 | 173.16 | N/A | N/A | N/A |
| DSP Healthcare Fund | 2,967,600 | 5.27 | 167.49 | N/A | N/A | N/A |
| DSP Large & Mid Cap Fund | 2,762,648 | 0.91 | 155.92 | N/A | N/A | N/A |
| Axis Small Cap Fund | 2,540,619 | 0.54 | 143.39 | N/A | N/A | N/A |
| DSP Flexi Cap Fund | 2,453,891 | 1.12 | 138.5 | N/A | N/A | N/A |
| Canara Robeco Small Cap Fund | 2,261,293 | 0.98 | 127.63 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -7.37 | -4.82 | -6.63 | -9.57 | -5.67 |
| Diluted EPS (Rs.) | -7.37 | -4.82 | -6.63 | -9.57 | -5.67 |
| Cash EPS (Rs.) | -7.10 | -4.52 | -5.12 | -8.09 | -5.33 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 5.04 | 12.38 | 17.21 | 6.61 | 8.49 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 5.04 | 12.38 | 17.21 | 6.61 | 8.49 |
| Revenue From Operations / Share (Rs.) | 0.30 | 0.53 | 0.62 | 0.81 | 1.06 |
| PBDIT / Share (Rs.) | -7.10 | -4.90 | -5.39 | -8.05 | -5.68 |
| PBIT / Share (Rs.) | -7.37 | -5.20 | -5.69 | -8.35 | -6.02 |
| PBT / Share (Rs.) | -7.37 | -4.86 | -5.42 | -8.39 | -6.09 |
| Net Profit / Share (Rs.) | -7.37 | -4.82 | -5.42 | -8.39 | -5.67 |
| NP After MI And SOA / Share (Rs.) | -7.37 | -4.82 | -5.42 | -8.39 | -5.67 |
| PBDIT Margin (%) | -2326.94 | -914.01 | -867.37 | -988.42 | -536.50 |
| PBIT Margin (%) | -2414.41 | -969.62 | -915.70 | -1025.51 | -568.75 |
| PBT Margin (%) | -2415.11 | -907.20 | -873.52 | -1029.98 | -574.80 |
| Net Profit Margin (%) | -2415.11 | -898.63 | -873.52 | -1029.98 | -535.31 |
| NP After MI And SOA Margin (%) | -2415.11 | -898.63 | -873.52 | -1029.98 | -535.31 |
| Return on Networth / Equity (%) | -146.14 | -38.91 | -31.51 | -126.88 | -66.80 |
| Return on Capital Employeed (%) | -143.86 | -41.77 | -32.81 | -121.80 | -68.13 |
| Return On Assets (%) | -118.90 | -36.88 | -30.41 | -112.92 | -56.18 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Asset Turnover Ratio (%) | 0.03 | 0.03 | 0.02 | 0.03 | 0.04 |
| Current Ratio (X) | 3.21 | 18.99 | 22.61 | 8.01 | 6.45 |
| Quick Ratio (X) | 3.20 | 18.94 | 22.61 | 8.01 | 6.45 |
| Inventory Turnover Ratio (X) | 14.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | -3323.53 | -674.71 | -406.21 | -220.85 | -88.68 |
| Interest Coverage Ratio (Post Tax) (X) | -3448.46 | -709.43 | -428.84 | -229.14 | -87.49 |
| Enterprise Value (Cr.) | 2435.23 | 2010.22 | 872.72 | 1343.38 | 849.81 |
| EV / Net Operating Revenue (X) | 365.88 | 171.92 | 64.46 | 113.42 | 63.05 |
| EV / EBITDA (X) | -15.72 | -18.81 | -7.43 | -11.47 | -11.75 |
| MarketCap / Net Operating Revenue (X) | 371.55 | 185.94 | 78.07 | 113.85 | 66.48 |
| Price / BV (X) | 22.48 | 8.05 | 2.82 | 14.02 | 8.30 |
| Price / Net Operating Revenue (X) | 371.56 | 185.97 | 78.08 | 113.85 | 66.48 |
| EarningsYield | -0.06 | -0.04 | -0.11 | -0.09 | -0.08 |
After reviewing the key financial ratios for Suven Life Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 5. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For Diluted EPS (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 5. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For Cash EPS (Rs.), as of Mar 25, the value is -7.10. This value is below the healthy minimum of 3. It has decreased from -4.52 (Mar 24) to -7.10, marking a decrease of 2.58.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.04. It has decreased from 12.38 (Mar 24) to 5.04, marking a decrease of 7.34.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.04. It has decreased from 12.38 (Mar 24) to 5.04, marking a decrease of 7.34.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.30. It has decreased from 0.53 (Mar 24) to 0.30, marking a decrease of 0.23.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -7.10. This value is below the healthy minimum of 2. It has decreased from -4.90 (Mar 24) to -7.10, marking a decrease of 2.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 0. It has decreased from -5.20 (Mar 24) to -7.37, marking a decrease of 2.17.
- For PBT / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 0. It has decreased from -4.86 (Mar 24) to -7.37, marking a decrease of 2.51.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 2. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 2. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For PBDIT Margin (%), as of Mar 25, the value is -2,326.94. This value is below the healthy minimum of 10. It has decreased from -914.01 (Mar 24) to -2,326.94, marking a decrease of 1,412.93.
- For PBIT Margin (%), as of Mar 25, the value is -2,414.41. This value is below the healthy minimum of 10. It has decreased from -969.62 (Mar 24) to -2,414.41, marking a decrease of 1,444.79.
- For PBT Margin (%), as of Mar 25, the value is -2,415.11. This value is below the healthy minimum of 10. It has decreased from -907.20 (Mar 24) to -2,415.11, marking a decrease of 1,507.91.
- For Net Profit Margin (%), as of Mar 25, the value is -2,415.11. This value is below the healthy minimum of 5. It has decreased from -898.63 (Mar 24) to -2,415.11, marking a decrease of 1,516.48.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -2,415.11. This value is below the healthy minimum of 8. It has decreased from -898.63 (Mar 24) to -2,415.11, marking a decrease of 1,516.48.
- For Return on Networth / Equity (%), as of Mar 25, the value is -146.14. This value is below the healthy minimum of 15. It has decreased from -38.91 (Mar 24) to -146.14, marking a decrease of 107.23.
- For Return on Capital Employeed (%), as of Mar 25, the value is -143.86. This value is below the healthy minimum of 10. It has decreased from -41.77 (Mar 24) to -143.86, marking a decrease of 102.09.
- For Return On Assets (%), as of Mar 25, the value is -118.90. This value is below the healthy minimum of 5. It has decreased from -36.88 (Mar 24) to -118.90, marking a decrease of 82.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.03. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Current Ratio (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has decreased from 18.99 (Mar 24) to 3.21, marking a decrease of 15.78.
- For Quick Ratio (X), as of Mar 25, the value is 3.20. This value exceeds the healthy maximum of 2. It has decreased from 18.94 (Mar 24) to 3.20, marking a decrease of 15.74.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 14.07. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 14.07, marking an increase of 14.07.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -3,323.53. This value is below the healthy minimum of 3. It has decreased from -674.71 (Mar 24) to -3,323.53, marking a decrease of 2,648.82.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -3,448.46. This value is below the healthy minimum of 3. It has decreased from -709.43 (Mar 24) to -3,448.46, marking a decrease of 2,739.03.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,435.23. It has increased from 2,010.22 (Mar 24) to 2,435.23, marking an increase of 425.01.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 365.88. This value exceeds the healthy maximum of 3. It has increased from 171.92 (Mar 24) to 365.88, marking an increase of 193.96.
- For EV / EBITDA (X), as of Mar 25, the value is -15.72. This value is below the healthy minimum of 5. It has increased from -18.81 (Mar 24) to -15.72, marking an increase of 3.09.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 371.55. This value exceeds the healthy maximum of 3. It has increased from 185.94 (Mar 24) to 371.55, marking an increase of 185.61.
- For Price / BV (X), as of Mar 25, the value is 22.48. This value exceeds the healthy maximum of 3. It has increased from 8.05 (Mar 24) to 22.48, marking an increase of 14.43.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 371.56. This value exceeds the healthy maximum of 3. It has increased from 185.97 (Mar 24) to 371.56, marking an increase of 185.59.
- For EarningsYield, as of Mar 25, the value is -0.06. This value is below the healthy minimum of 5. It has decreased from -0.04 (Mar 24) to -0.06, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Suven Life Sciences Ltd:
- Net Profit Margin: -2415.11%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -143.86% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -146.14% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -3448.46
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.2
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 54.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -2415.11%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 215 Atrium, C Wing, 8th Floor, Mumbai Maharashtra 400093 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vivek Sharma | Executive Chairman |
| Dr. V Prasada Raju | Managing Director |
| Mr. Pankaj Patwari | Non Executive Director |
| Ms. Shweta Jalan | Non Executive Director |
| Mr. Vinod Padikkal | Non Executive Director |
| Mr. Vinod Rao | Independent Director |
| Mr. K G Ananthakrishnan | Independent Director |
| Mr. U B Pravin Rao | Independent Director |
| Ms. Matangi Gowrishankar | Independent Director |
| Mr. Jai Shankar Krishnan | Independent Director |
FAQ
What is the intrinsic value of Suven Life Sciences Ltd?
Suven Life Sciences Ltd's intrinsic value (as of 06 January 2026) is ₹132.35 which is 19.79% lower the current market price of ₹165.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,749 Cr. market cap, FY2025-2026 high/low of ₹303/102, reserves of ₹259 Cr, and liabilities of ₹337 Cr.
What is the Market Cap of Suven Life Sciences Ltd?
The Market Cap of Suven Life Sciences Ltd is 3,749 Cr..
What is the current Stock Price of Suven Life Sciences Ltd as on 06 January 2026?
The current stock price of Suven Life Sciences Ltd as on 06 January 2026 is ₹165.
What is the High / Low of Suven Life Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Suven Life Sciences Ltd stocks is ₹303/102.
What is the Stock P/E of Suven Life Sciences Ltd?
The Stock P/E of Suven Life Sciences Ltd is .
What is the Book Value of Suven Life Sciences Ltd?
The Book Value of Suven Life Sciences Ltd is 12.4.
What is the Dividend Yield of Suven Life Sciences Ltd?
The Dividend Yield of Suven Life Sciences Ltd is 0.00 %.
What is the ROCE of Suven Life Sciences Ltd?
The ROCE of Suven Life Sciences Ltd is 87.0 %.
What is the ROE of Suven Life Sciences Ltd?
The ROE of Suven Life Sciences Ltd is 87.2 %.
What is the Face Value of Suven Life Sciences Ltd?
The Face Value of Suven Life Sciences Ltd is 1.00.